Metabotyping human endometrioid endometrial adenocarcinoma reveals an implication of endocannabinoid metabolism
Metrics: PDF 1651 views | HTML 2592 views | ?
Mariona Jové1,*, Sònia Gatius2,*, Andree Yeramian2, Manuel Portero-Otin1, Núria Eritja2, Maria Santacana2, Eva Colas2, Maria Ruiz2, Reinald Pamplona1, Xavier Matias-Guiu2
1Department of Experimental Medicine, Universitat de Lleida, IRBLleida, E-25198, Lleida, Spain
2Department of Pathology and Molecular Genetics/Oncologic Pathology Group, Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLleida, E-25198, Lleida, Spain
*These authors have contributed equally to this work
Reinald Pamplona, email: [email protected]
Xavier Matias-Guiu, email: [email protected]
Keywords: endocannabinoid system, metabolomic profile, endometrioid endometrial carcinoma, mass spectrometry, personalized medicine
Received: February 12, 2016 Accepted: June 09, 2016 Published: July 13, 2016
Metabolomics, an essential technique in precision medicine, contributes to the molecular fingerprinting of tumours, further helping to understand their pathogenesis. In this work, using a LC-ESI-QTOF-MS/MS platform, we demonstrated the existence of a specific metabolomic signature which could define endometrioid endometrial carcinoma (EEC), arising the endocannabinoid system as a potential pathway involved in EC pathogenesis. Metabolomics could also shed light in the processes involved in myometrial invasion, proposing new targets for possible therapeutic intervention. Consequently, we also described a different metabolomic profile in surface endometrioid carcinoma and myometrial invasive front. We validated pathways disclosed by metabolomics by immunohistochemistry. Specifically, endocannabinoid and purine metabolism could be involved in tumor myometrial invasion.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.